Puma Biotechnology Inc (PBYI) was Reiterated by Credit Suisse to “Outperform” according to the research note released today. The brokerage firm has raised the Price Target to $ 111 from a previous price target of $54 . Credit Suisse advised their investors in a research report released on Sep 22, 2016.
Many Wall Street Analysts have commented on Puma Biotechnology Inc. Company shares were Upgraded by Stifel on Sep 21, 2016 to ” Buy”, Firm has raised the Price Target to $ 88 from a previous price target of $61 .
Puma Biotechnology Inc opened for trading at $64.42 and hit $68 on the upside on Tuesday, eventually ending the session at $65.16, with a gain of 10.53% or 6.21 points. The heightened volatility saw the trading volume jump to 34,80,277 shares. Company has a market cap of $2,117 M.
In a different news, on Jul 8, 2015, Richard Paul Bryce (SR VP, CLINICAL RESEARCH & DEV) sold 3,000 shares at $110.03 per share price.
Puma Biotechnology Inc. is a biopharmaceutical company that focuses on the acquisition development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive breast cancer and patients with non-small cell lung cancer breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors HER1 HER2 and HER4.